TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK demonstrated statistically significant overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results... Read more.
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
TIVDAK demonstrated superior overall survival, progression-free survival and objective response rate compared to chemotherapy in late-breaking results presented... Read more.
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Death by More Than Half Versus Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
KEYTRUDA plus enfortumab vedotin significantly prolonged overall survival (OS) by 53% – an improvement in median OS of more than 15 months – compared... Read more.
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
– Risk of death was reduced by 53% in patients treated with enfortumab vedotin plus pembrolizumab compared to chemotherapy – – Enfortumab vedotin plus pembrolizumab... Read more.
Unit21 Launches Real-Time Monitoring to Fight Real-Time Fraud
LAS VEGAS–(BUSINESS WIRE)–#Money2020–Unit21, a leading provider in risk and compliance solutions, today announced the launch of Real-Time Monitoring... Read more.
Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial
AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan plus IMFINZI showed a confirmed objective response rate of 79% Two ongoing Phase III trials are evaluating... Read more.
Raludotatug Deruxtecan Continues to Demonstrate Promising Clinical Activity in Patients with Advanced Ovarian Cancer in Early Trial
Encouraging overall response rate of 46% and disease control rate of 98% with a median duration of response of 11.2 months seen with raludotatug deruxtecan in heavily... Read more.
Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab showed a confirmed objective response rate of 79% Two ongoing phase 3 trials are evaluating... Read more.
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
– Cabozantinib compared with placebo reduced the risk of disease progression or death in patients with pancreatic NET and in patients with extra-pancreatic NET... Read more.
Faraday Future to Deliver FF 91 2.0 Futurist Alliance to World Champion Race Car Driver Justin Bell on October 24
LOS ANGELES–(BUSINESS WIRE)–Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”), a California-based... Read more.